title: Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma.
abstract: Renal cell carcinoma (RCC) is the most common neoplasm of the kidney. We conducted an integrated analysis of copy number, gene expression (mRNA and miRNA), protein expression, and methylation changes in clear cell renal cell carcinoma (ccRCC). We used a stepwise approach to identify the most significant copy number aberrations (CNA) and identified regions of peak and broad copy number gain and loss, including peak gains (3q21, 5q32, 5q34-q35, 7p11, 7q21, 8q24, 11q13, and 12q14) and deletions (1p36, 2q34-q37, 3p25, 4q33-q35, 6q23-q27, and 9p21). These regions harbor novel tumor-related genes and miRNAs not previously reported in renal carcinoma. Integration of genome-wide expression data and gene set enrichment analysis revealed 75 gene sets significantly altered in tumors with CNAs compared with tumors without aberration. We also identified genes located in peak CNAs with concordant methylation changes (hypomethylated in copy number gains such as STC2 and CCND1 and hypermethylated in deletions such as CLCNKB, VHL, and CDKN2A/2B). For other genes, such as CA9, expression represents the net outcome of opposing forces (deletion and hypomethylation) that also significantly influences patient survival. We also validated the prognostic value of miRNA let-7i in RCCs. miR-138, located in chromosome 3p deletion, was also found to have suppressive effects on tumor proliferation and migration abilities. Our findings provide a significant advance in the delineation of the ccRCC genome by better defining the impact of CNAs in conjunction with methylation changes on the expression of cancer-related genes, miRNAs, and proteins and their influence on patient survival.
authors.affiliation: Department of Laboratory Medicine, and the Keenan Research Centre in the Li Ka Shing Knowledge Institute St. Michael's Hospital, Toronto, Canada.
authors.forename: Andrew H
authors.initials: AH
authors.lastname: Girgis
authors.forename: Vladimir V
authors.initials: VV
authors.lastname: Iakovlev
authors.forename: Ben
authors.initials: B
authors.lastname: Beheshti
authors.forename: Jane
authors.initials: J
authors.lastname: Bayani
authors.forename: Jeremy A
authors.initials: JA
authors.lastname: Squire
authors.forename: Anna
authors.initials: A
authors.lastname: Bui
authors.forename: Marina
authors.initials: M
authors.lastname: Mankaruos
authors.forename: Youssef
authors.initials: Y
authors.lastname: Youssef
authors.forename: Bishoy
authors.initials: B
authors.lastname: Khalil
authors.forename: Heba
authors.initials: H
authors.lastname: Khella
authors.forename: Maria
authors.initials: M
authors.lastname: Pasic
authors.forename: George M
authors.initials: GM
authors.lastname: Yousef
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics*; D002292:Carcinoma, Renal Cell / Q000235:genetics* / Q000473:pathology; D002874:Chromosome Mapping; D018628:Gene Dosage; D015894:Genome, Human; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007680:Kidney Neoplasms / Q000235:genetics* / Q000473:pathology; D009693:Nucleic Acid Hybridization; D060888:Real-Time Polymerase Chain Reaction
chemical_list: D014408:Biomarkers, Tumor